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Aims Randomized clinical trials investigating a possible outcome effect of remote monitoring in patients with implantable
defibrillators have shown conflicting results. This study analyses the information flow and workflow details from
the IN-TIME study and discusses whether differences of message content, information speed and completeness,
and workflow may contribute to the heterogeneous results.
...................................................................................................................................................................................................
Methods
and results
IN-TIME randomized 664 patients with an implantable cardioverter/defibrillator indication to daily remote monitor-
ing vs. control. After 12 months, a composite clinical score and all-cause mortality were improved in the remote
monitoring arm. Messages were received on 83.1% of out-of-hospital days. Daily transmissions were interrupted
2.3 times per patient-year for more than 3 days. During 1 year, absolute transmission success declined by 3.3%.
Information on medical events was available after 1 day (3 days) in 83.1% (94.3%) of the cases. On all working days,
a central monitoring unit informed investigators of protocol defined events. Investigators contacted patients with a
median delay of 1 day and arranged follow-ups, the majority of which took place within 1 week of the event being
available.
...................................................................................................................................................................................................
Conclusion Only limited data on the information flow and workflow have been published from other studies which failed to
improve outcome. However, a comparison of those data to IN-TIME suggest that the ability to see a patient early
after clinical events may be inferior to the set-up in IN-TIME. These differences may be responsible for the hetero-
geneity found in clinical effectiveness of remote monitoring concepts.
                                                                                                                                                                                                                   
Keywords Telemedicine • Defibrillator • implantatble • Heart failure
Introduction
Remote monitoring (RM) of implantable cardioverter-defibrillators
(ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds)
has become widely available and is recommended by the HRS/EHRA
expert consensus panels from 2008 on.1,2 State-of-the-art RM tech-
nology allows automatic transmission of data related to device func-
tion, arrhythmias, and other physiological parameters without active
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participation of the patient.2–9 Remote monitoring enables safe reduc-
tion of the in-person follow-up (FU) burden for patient and clinician
convenience and a substantial shortening of the delay between a clin-
ically actionable event detected by the device and the clinical
reaction.2,4,6,10
The potential influence of RM on patient outcomes has been inves-
tigated in randomized controlled trials (RCTs) employing a variety of
RM technologies in various healthcare models.11–13 To date, only the
IN-TIME trial8 demonstrated a significant impact of implant-based
RM on hard clinical endpoints, a composite clinical score for heart
failure patients14 (primary endpoint of the study) and mortality. In
eight other RCTs included in a dedicated meta-analysis (2015)15 and
in three recent trials (2016–17),16–18 RM failed to improve patient
outcomes. However, a pooled patient-level analysis of the TRUST,4
ECOST,19 and IN-TIME8 results (2010–14) with the same RM sys-
tem, confirmed the benefit reported in the IN-TIME and suggested
that it was driven by the prevention of heart failure exacerbation.20
The question arises why the results with this particular RM system
differ from those of other systems.
It is generally plausible that a clinical effect of RM can be conferred
only if relevant information on the patient’s medical status is received
in time and if it leads to important therapeutic changes.21 The present
article reports details of the information flow (content and informa-
tion speed) and workflow in the IN-TIME trial. Its aim is to discuss
whether a difference in these aspects across studies may be respon-
sible for different clinical outcomes, with IN-TIME being an ‘outlier’
not because of chance or a faulty analysis or interpretation, but due
to differences in study set-up and RM technology.
Methods
IN-TIME study design and results
The IN-TIME study design and main results have been published else-
where.8,11 In brief, the study enrolled 716 patients with chronic heart fail-
ure, New York Heart Association (NYHA) Class II/III symptoms, ejection
fraction <_35%, no permanent atrial fibrillation (AF), and an indication for
dual-chamber ICD or CRT-D treatment. After a run-in phase of 1 month,
patients were randomly assigned to either automatic, daily RM in addition
to optimal care (n = 333) or optimal care without RM (n = 331). After
12 months of FU, the prevalence of a worsened composite clinical score,
combining all-cause death, overnight hospitalization for heart failure, in-
crease in NYHA class, and worsening in patient’s global self-assessment,14
was 18.9% in the RM group vs. 27.2% in the control group (P = 0.013).8
The Kaplan–Meier estimate of all-cause mortality was 3.4% vs. 8.7%
(P = 0.004).
The proprietary Biotronik Home MonitoringVR (HM) technology
(Biotronik SE & Co. KG, Berlin, Germany) was used. Everyday, the
implanted devices sent data wirelessly to the Home Monitoring Service
Center (HMSC) via a patient device situated at the patient’s bedside. The
only patient activity required was to connect once the patient device to a
power line. The kind of transmitted data is summarized in Table 1. The
HMSC processes incoming data and posts them as trend graphs and
tables on a secure website for treating physicians. Furthermore, it sends
e-mails (‘HM-alerts’) when criteria, which can be adapted online for indi-
vidual patient, are met. In IN-TIME, HM data were transmitted irrespect-
ive of the randomization group but were concealed for control patients
until study completion. Four patients (0.6%) with poor data transmission
during the run-in phase were excluded from randomization.
Home Monitoring information flow in IN-TIME is summarized in Figure 1.
In contrast to normal HM routines, HM-alerts from the HMSC were
sent to a central monitoring unit (CMU) located at an investigational
site in Leipzig.8 The CMU had standard operating procedures which
defined study specific alerts, mostly based on HM-alerts (Table 2). Study
nurses, supported by local physicians, screened all patients’ data during
normal office working hours (Mondays–Fridays), alerted sites and
required confirmation of alert receipt. Investigators could ask for modi-
fication of alerts for specific patients. The CMU was established to tailor
the alerts specifically for the study, to enhance sites’ awareness of alerts,
and to record alerts and receipt confirmations systematically. The
...................................................................................
Table 1 Data received in the Home Monitoring
Service Center on a daily basis
Trend data
Bradycardia and CRT
Pacing statistics for all pacing channels
Atrioventricular conduction statistics
Percentage of CRT pacing
HF monitor and physiological parameters
Mean atrial heart rate
Mean ventricular heart rate
Mean ventricular heart rate at rest
Mean number of VES per hour
Atrial heart rate variability
Patient activity in hours per day
Thoracic impedancea
Atrial tachyarrhythmia
Atrial burden (percent of the day in AF)
Mean and maximum ventricular rate during AF
SVT episode (counter)
Mode switch (counter)
Ventricular tachyarrhythmia
VT1, VT2, and VF zone detected (counter)
ATP and shock therapies, started/successful (counters)
Ineffective shock with maximum energy (counter)
Lead related
RA, RV, and LV shock impedance
RA amplitude (mean)
RV, LV amplitude (minimum)
RV, LVa pacing threshold
Technical
Actual device programming setting
Battery and technical status
IEGM episode (typically one per day)
VT1, VT2, VF, or SVT episode
Atrial monitoring episode
Periodic IEGM
All data are transmitted on a daily basis and displayed as trends or listings.
AF, atrial fibrillation; ATP, antitachycardia pacing; CRT, cardiac resynchronization
therapy; HF, heart failure; IEGM, intracardiac electrogram; LV, left ventricular;
RA, right atrial; RV, right ventricular; SVT, supraventricular tachyarrhythmia; VES,
ventricular extrasystoles; VF, ventricular fibrillation; VT1/VT2, slow/fast ventricu-
lar tachycardia.
aAvailable in one-third of implanted study devices.
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CMU staff did not assist in diagnostic or therapeutic decisions, except
that they checked intracardiac electrogram snapshots for suspicious
content.
If the investigators considered the content of the alert clinically rele-
vant, they were supposed to contact the patient and conduct a structured
interview on the patient’s overall condition, weight change, and drug
compliance. After gaps in RM transmission, this interview was also con-
ducted to confirm the patient’s status after a period without monitoring
data. Per patient-year of FU, the CMU sent 4.0 alerts to the sites, the sites
contacted the patient 2.1 times, and 0.3 additional FUs or contacts to
other physicians were arranged.8 Investigators were suggested to react
according to current guidelines but the therapeutic consequences were
not followed.
Data analysis
The present analysis of IN-TIME data aims at evaluating the transmission
performance of HM, describing the CMU performance, and estimating
delays from alerts to FU visits. The following aspects are addressed as
follows:
Establishing HM transmission: the time from post-implant hospital dis-
charge to first HM transmission described by the Kaplan–Meier method,
in all patients with successful implantation including some not who were
not randomized at 1 month.
Transmission performance: the number of days with HM message divided
by the total days between randomization and study termination. Also the
length of transmission gaps was analysed.
Decline of transmission during the study: a linear fit of the share of patients
with a HM message as a function of time after randomization, weighted
with the number of patients in the study.
Delay from an event until the information is received in the HMSC: an esti-
mation based on the distribution of the time to the next successful trans-
mission for all days between randomization and study termination in
patients randomized to RM.
Working time compliance of the CMU: we estimated whether the CMU
worked on every working day. For this, we selected a period of 2 years
when most patients were included in the study and calculated the mean
number of CMU alerts per day and the number of 7 days of the week
(Mondays, Tuesdays, . . ., Sundays) without any alert. The Poisson-
distribution predicts an expected number of days without any alert from
the mean number of alerts per day, assuming that alerts were independent
of each other. If the CMU did not comply with their working time rules, a
higher than predicted number of days without alerts would be expected.
Delay from alert to patient contact and follow-up: the delay from a HM
alert to a patient contact was recorded in the study documentation.
However, the delay from a HM alert to related FU visits was not available
because the study data do not allow an assignment of FUs to alerts. We,
therefore, estimated alert-to-FU delays without any a priori assumptions
on relations between FUs and alerts by a mathematical model. It used as
inputs 1222 alerts and 1289 FUs captured on case report forms or evi-
dent in the HMSC as dates of reprogramming in 280 patients who had
alerts in the RM group. For each patient, we calculated the set of time
intervals between each alert and each FU. We show the relative number
of FUs per day in the 8 weeks after the alert, as mean and standard
deviation, normalized to the FU rate between 14 and 100 days after the
alert.
Statistical methods
Home Monitoring performances had non-normal distributions and were
compared with the Mann–Whitney U-test. We used a linear regression
model to calculate the decline of HM transmission after randomization. A
P-value <0.05 was considered statistically significant. The analysis was
conducted with the R 3.3 statistical software (R Development Core
Team, Vienna, Austria).
Results
Transmission performance of home
monitoring
Of 702 patients discharged from hospital with a study device
implanted, 41.6% had HM transmission established already 1 day after
discharge, 68.8% on Day 3, and 95.5% on Day 30.
Clinic A
Device Paents
Clinic A
Clinic B
Clinic C
Home Monitoring 
Database
Central 
Monitoring Unit
Clinic B
Clinic C
Transmit implant data 
via cellular network
(daily, fully automac)
Evaluates HM alerts, 
idenfies IN-TIME events 
and send to responsible 
clinic (MO-FR)
Evaluates incoming 
data and sends HM 
alerts to CMU 
(daily, automac)   
Contacts paent if 
IN-TIME event is clinically 
relevant (MO-FR)
Confirms and checks HM data 
to decide whether paent 
contact is necessary (MO-FR) Acknowledges 
recepon of IN-TIME 
event (MO-FR)
IN-TIME
IN-TIME
Acknowledges 
recepon of IN-TIME 
event (MO-FR)
Figure 1 Sketch of the remote monitoring information flow and interaction between parties in IN-TIME. CMU, clinical monitoring unit; HM, Home
Monitoring.
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Table 2 Alerts sent to investigational sites by the central monitoring unit in IN-TIME: definitions and occurrencesa
Alert type Device/HMSC: alert
setting
CMU activity in a pa-
tient with HMSC alert
CMU: condition for SOP
compatible event
Number of alerts
(number of patients)
Atrial tachyarrhythmia 109 (65)
First onset of AF for >30 s
in patients with no prior
documented AF
Device: IEGM for atrial moni-
toring episode
Check IEGM for atrial moni-
toring episode in patients
with no prior documented
AF
IEGM shows true AF 31 (31)
HMSC: sends alert
Long atrial arrhythmia
episode (>6 h) with
high-ventricular rate
(>120 b.p.m.)
HMSC: alert for atrial burden
>6 h with ventricular rate
>120 b.p.m.
Check IEGM Ventricular rate >120 b.p.m. None
Daily AF burden >50% on
7 consecutive days after a
period of 4 weeks with
burden <25% for patients
with known AF
HMSC: alert for atrial burden
>6 h
Check trend graph Atrial burden >_50% on 7 con-
secutive days
20 (16)
Atrial arrhythmia in the
VT zone
HMSC: VT zone detected Check IEGM Suspicious IEGM 1 (1)
First onset of AF for >30 s
in patients with prior
documented AF
Device: IEGM for atrial moni-
toring episode
Check IEGM for atrial moni-
toring episode
Not predefined 22 (22)
HMSC: alert for atrial moni-
toring episode
Atrial episode HMSC: alert for atrial moni-
toring episode
Check IEGM for atrial moni-
toring episode
Not predefined 22 (14)
Atrial burden >50% for
more or less than 1 week
HMSC: alert for atrial burden
>_6 h
Check trend graph Not predefined 13 (8)
Ventricular tachyarrhythmia or ICD shock 56 (42)
>_3 VT2/VF episodes over
48 h
HMSC: alerts for VT2 and VF
detection
Check IEGM for appropriate-
ness and count true VT/VF
episodes in 48 h
>_3 episodes within 48 h 7 (6)
First ICD shock in spon-
taneous episode
HMSC: alert for VT and VF
detections
Check if the episode was
induced or spontaneous
Spontaneous episodes with
shock
22 (22)
First occurrence of slow
VT (<150 b.p.m.)
HMSC: alert for VT1 (moni-
toring zone)
Check IEGM if true VT True VT <150 b.p.m. 8 (8)
VT/VF detection with sus-
picious IEGM (e.g. sensing
issue or inappropriate
detection)
HMSC: alert for VT and VF
detections
Check IEGM Suspicious IEGM 2 (2)
<3 VT/VF episodes over
48 h
HMSC: alert for VT and VF
detections
Check IEGM Not predefined 18 (14)
Ineffective ICD shock HMSC: ineffective shock Check IEGM Not predefined 2 (2)
VT and low CRT pacing HMSC: alert for VT and low
CRT
Check IEGM Not predefined 1 (1)
Low percentage of CRT pacing 91 (35)
CRT pacing <80% over
48 h
HMSC: alert for CRT pacing
<80%
Check CRT pacing on the day
before
CRT pacing <80% on two
consecutive days
81 (30)
CRT pacing <80% com-
bined with IEGM
HMSC: alert for CRT pacing
<80%
Check IEGM Suspicious IEGM 3 (3)
CRT pacing <80% over
24 h
HMSC: alert for CRT pacing
<80%
Check trend graph Not predefined 8 (7)
CRT pacing <80% and
ventricular or atrial
arrhythmia
HMSC: alert for CRT pacing
<80%
Check IEGM Not predefined 2 (2)
Continued
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In the RM group, HM messages were received on 82.2% of all
patient-days, or on 83.1% out-of-hospital days after randomization.
Patient-individually, the median percentage of days with a message
was higher in the RM group [87.8%, interquartile range (IQR): 78.6–
93.4%] than in the control group (85.4%, IQR: 71.8–91.8%)
(P = 0.003). In the RM group, 79.9% of the patients transmitted mes-
sages on 75% or more of all study days.
There were 29.5 transmission interruptions per patient-year in the
RM group with an average length of 2.1 days, but only 2.3 interrup-
tions per year were longer than 3 days. In the control group, the total
number of interruptions was similar (29.2 per patient-year), but inter-
ruptions longer than 3 days were more frequent (2.8 per patient-
year).
A decline of transmission performance during the study was
observed in both randomization groups (Figure 2). The linear fit line
fell by an absolute of 3.3%, from 84.7% (randomization) to 81.4%
(365 days), in the RM group, and by 10.1%, from 83.4% to 73.3%, in
the control group.
The estimated delay between a medical event and the information
being received in the HMSC was 1 day in 83.1% of all cases. On Days
2 and 3, 91.2% and 94.3% of all events were available, respectively.
Definition and occurrence of alerts sent
by the central monitoring unit
Table 2 summarizes CMU alerts. For example, the first AF episode
was reported in 31 patients without history of AF. Twenty alerts
were sent for daily AF burden >_50% on 7 consecutive days. A first
ICD shock triggered by spontaneous ventricular tachyarrhythmia
was reported in 22 patients, whereas arrhythmia ‘storm’ (>_3
....................................................................................................................................................................................................................
Table 2 Continued
Alert type Device/HMSC: alert
setting
CMU activity in a pa-
tient with HMSC alert
CMU: condition for SOP
compatible event
Number of alerts
(number of patients)
Ventricular extrasystoles 54 (46)
Visible upward trend in
VES/h over 7 days
Not programmable Check trend graph weekly Visible trend 39 (34)
VES >110 per hour for
more than 10 days
Not programmable Check trend graph Not predefined 15 (15)
Physiological trends 2 (2)
Visible downward trend in
patient activity over 7
days
Not programmable Check rend graph weekly Visible trend 1 (1)
Rising mean heart rate Not programmable Check trend graph Not predefined 1 (1)
Lead related measurements and IEGMs 98 (58)
Suspicious IEGMb HMSC: alert for any new
IEGM
Check IEGM Suspicious IEGM 25 (18)
RA amplitude HMSC: programmable Check trend graph <0.5 mV 13 (9)
RV amplitude HMSC: programmable Check trend graph <2.0 mV 22 (18)
RV pacing threshold HMSC: programmable Check trend graph Safety margin <1 V 11 (10)
RV impedance HMSC: programmable Check trend graph <250 or >1500 Ohm 1 (1)
LV amplitude HMSC: programmable Check trend graph <2.0 mV None
LV impedance HMSC: programmable Check trend graph <250 or >1500 Ohm 2 (2)
LV pacing threshold HMSC: programmable Check trend graph Safety margin <1 V 12 (8)
Shock impedance HMSC: programmable Check trend graph <30 or >125 Ohm 13 ( 5)
Gaps in data transmission 818 (241)
Missing HM messages for
3 days
HMSC: alert for missing mes-
sages for 3 days
Check if the patient is known
to be on holidays or in
hospital
If the patient is not known to
be absent
818 (241)
Technical alerts None
Elective replacement
indicator
HMSC: programmable None
Technical alert HMSC: programmable None
Sums of numbers of alerts do not match completely because few alerts are contained in more than one category, and three alerts contained no description of the content.
CMU, central monitoring unit; ICD, implantable cardioverter-defibrillator; HM, Home Monitoring; SOP, standard operating procedure defined in the study protocol; VT,
ventricular tachycardia; AF, atrial fibrillation; CRT, cardiac resynchronization therapy; IEGM, intracardiac electrogram; LV, left ventricular; RA, right atrial; RV, right ventricular;
VES, ventricular extrasystoles; VF, ventricular fibrillation; VT1/VT2, slow/fast ventricular tachycardia.
aDuring the randomized period in the RM group.
bT-wave oversensing, far-field atrial sensing of ventricular activity, or other suspected sensing problem.
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ventricular episodes over 48 h) led to seven alerts. Low percentage
of CRT pacing over two consecutive days was reported 83 times.
Beyond alerts predefined in the study protocol, the CMU sent self-
initiatively notifications for a first AF episode in patients with known
AF history and for some other conditions (Table 2).
Working time compliance of the central
monitoring unit
In a period of 104 weeks between 1 July 2008 and 28 June 2010, on
average 113 patients (between 73 and 140) were followed by the
CMU. For these patients, the CMU sent 938 alerts, or 1.29 alerts per
day. No alerts were sent on 12.5% of all Mondays (13/104), on 30.0%
of all Tuesdays–Fridays (Tuesdays 29/104, Wednesdays 30/104,
Thursdays 31/104, and Fridays 35/104), and on 85.1% of all Saturdays
and Sundays (Saturdays 86/104 and Sundays 91/104) in this period.
The data indicate that the CMU did not work during most weekends,
as defined per study protocol, and that a backlog of alerts remained
for Mondays. The Poisson-distribution predicts no alerts on 27.5% of
all days, which is close to the result for Tuesdays–Fridays, indicating
good working time compliance.
Delay from alert to patient contact and
follow-up (estimated)
Patients were contacted after a median delay of 1 day (IQR 0–6 days).
Figure 3 shows that the number of FUs is clearly increased by a factor
of two in the week after the alert, but only very slightly in the second
week, suggesting that FUs, which were conducted as a consequence
of HM information took place in most cases within a week of the
alert. A sketch of some performance figures is given in Figure 4.
Discussion
To understand whether differences in clinical outcomes of implant-
based RM in different studies can be attributed to differences in
study set-up, we analysed the information flow and workflow in the
Figure 2 Percentage of patients with home monitoring data
transmission on any given day between randomization and study
termination. Black line denotes the RM group and red line denotes
the control group. The straight lines are the linear fits. The linear re-
gression model shows that the decline was statistically significant in
both groups (P < 0.001).
Figure 3 Increase of follow-ups after alerts. Based on 1222 alerts and 1289 follow-ups in 280 patients who had alerts in the RM group. We calcu-
lated the set of time intervals between each alert and all follow-ups following in the same patient. We show the relative number of follow-ups per day
in the 8 weeks after the alert, as mean and standard deviation, normalized to the follow-up rate between 14 and 100 days after the alert. Note that the
number of follow-ups is increased in the week after the alert, but not later. This suggests that most follow-ups resulting as a consequence of home
monitoring information took place within a week of the alert.
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IN-TIME trial. Three main possible sources of heterogeneity between
studies will be discussed: content of RM messages, information speed
and completeness, and workflow in response to RM messages.
Content of remote monitoring messages
In the IN-TIME study, a multitude of different triggers was used to
generate alerts. When treating physicians examined the patients’
data, they had access to up-to-date data trends for most variables
stored in the device statistics, including arrhythmia burden, heart
rates, patient activity, intracardiac electrograms, and pacemaker tim-
ing statistics. These data may help with the decision if an alert, mostly
derived from a single variable, is appropriate. The possibility to mod-
ify the alert criteria online without reprogramming the implanted de-
vice may reduce inappropriate alerts and increase the physician’s
willingness to act.
In other studies, the number of possible alerts was seemingly lim-
ited by study design (thoracic impedance only12) or by the RM system
(e.g. five alerts available: thoracic impedance, atrial burden, ventricu-
lar rate during AF, high number of shocks per episode, and all thera-
pies exhausted).22,23 It is unclear from the publications of these
studies which up-to-date data were available when an alert was
received to review the patient’s condition and decide about the clin-
ical need for a patient contact. At least in one study, a patient contact
and a manual data download was required after automatic alerts to
allow for RM data review.12 In REM-HF, no alerts were programmed
but a complete data set was checked after every transmission (sched-
uled once per week).13
Speed and completeness
The results on HM transmission in IN-TIME show that HM is suited
for long-term monitoring in consecutive unselected ICD/CRT-D
recipients. Within 1 month of implantation, 95% of all patients had
successfully sent a first message. Less than 1% of patients were
excluded from the study due to inability to establish HM transmis-
sion. Only 3.3% of surviving patients in the RM group who sent mes-
sages in the beginning failed to do so after 1 year. The fact that
messages were still received on more than 70% of all patient-days in
control group patients after being left alone for 1 year suggests that
the transmission is robust. However, the early reaction to interrup-
tions of the transmission, which is only possible with frequent sched-
uled transmission, exerts a significant effect on transmission
performance.
In REM-HF, 58%, 66%, and 62% of the patients successfully trans-
mitted 75% or more of the scheduled weekly messages, at 6, 12, and
24 months, respectively.13 The corresponding figure from IN-TIME is
80%; this is higher, but the main difference is that messages were
scheduled daily, not weekly. Since no alerts were transmitted in
REM-HF, changes in the patient’s status were detected only in the
next scheduled transmission.
In the CONNECT study, 180 of 575 clinical events resulted in a
transmitted alert (31%).6 The devices used in this study could trans-
mit each type of alert only once between FUs. Other studies
reported a better rate of alerts transmission: 76% (OptiLink)16 and
88% (MORE-CARE).17
In the RM system used in IN-TIME, alerts are not generated in the
device but in the service centre. Because most alerts are based on a
comparison between the recent and the previous transmission, alerts
will not be lost even if the transmission on that day fails. About 83%
of all events detected in the RM group were available in the HMSC
within 1 day, and approximately 94% were available within 3 days.
The median delay until the contact to the patient—if a contact took
place—was 1 day. The delay between the events and their availability
in the RM service centre has not been reported from other trials.
The median delay between alerts and their reviewing 1.4 days in
EVOLVO7 and 3 days in MORE-CARE.24
Workflow
The IN-TIME study protocol required checking of the transmitted
HM data in the CMU on all working days. Although the chain from
medical event to clinical action cannot be reconstructed exactly, the
data indicate that the CMU fulfilled its duties. It worked on all days
between Mondays and Fridays, with stand-in for holidays and sick
RM
Service 
Center
Central 
Monitoring
Unit
Clinic PaentICD/CRT-D
Prompt 
in-office FU if 
interview is ‘posive’
(asap)
Daily 
automac 
transmission 
(Mo-Su)
Prompt 
paent contact if IN-TIME 
alert is clinically relevant 
(asap)
Daily 
RM alert evaluaon and 
classificaon as IN-TIME events
(Mo-Fr)
Device 
diagnoscs 
(last 24h)
RM alerts IN-TIME 
alerts
Structured
Interview
Immediate 
automac 
data processing  
(Mo-Su)
IN-TIME
365 messages
83% - 94%  received 
aer 1 - 3 day(s)
n.a. 
100% of HM alerts nofied 
on the same day
4.0 In-Time alerts
n.a.
Unl next working day
2.1 contacts
n.a.
Median 1 day [IQR 0 – 5]
ACTIVITY
WORKFLOW
PERFORMANCE
Events per paent year
Success
Delay
IN-TIME Workflow Performance
Less than one week
Figure 4 Sketch of the IN-TIME information- and workflow with some performance characteristics. HM, Home Monitoring; Mo, Monday;
Fr, Friday; Su, Sunday; FU, follow-up; asap, as soon as possible; n.a., not available; IQR, interquartile range.
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leave. The vast majority of CMU alerts were compliant with the pre-
defined rules, but some went beyond, such as the first AF episode in
patients with known history of AF. Whether this was by oversight or
on purpose, the information can be medically relevant. The feedback
to clinical sites on transmission gaps exerted a significant effect on
transmission performance, as evidenced by better transmission rate
in the RM group vs. the control group by absolute 8.1% late in the
study.
The analysis of the temporal relationship between alerts and FUs
indicated that most FUs took place within a week of the alert. The in-
formation speed and completeness (of alerts) is an obvious require-
ment for this result, but it is per se not sufficient without a daily check
of the RM data. We are not aware of publications of workflow details
from other studies, such as estimates of a delay from alert to FU.
Influence of remote monitoring on
outcome
With the presented data, we cannot prove that the difference be-
tween the results of IN-TIME and other studies has its cause in differ-
ent study set-ups or the RM system characteristics. However, RM
can influence outcome only through early appraisal of relevant med-
ical information by the physician. We have shown that in IN-TIME, a
considerable list of alerts was used; that the vast majority of alerts
was available within 1 day, together with a current set of diagnostic
data comparable to that in the device’s memory; and that the investi-
gators managed to see most patients within a week of an event, if
they decided that this was indicated. Comparable results are not
(yet?) reported for other studies, so we are not able to describe dif-
ferences with the required precision. However, several performance
characteristics reported here are inherently connected to the tech-
nology of the RM system used in IN-TIME, especially the ability to
transmit the complete data set daily.
A recent analysis of several clinical endpoints from the IN-TIME
and ECOST studies has suggested that daily HM improves only heart
failure events.20 The IN-TIME study was the first study to demon-
strate clinical benefit of implant-based RM, but it has been overseen
that it was also the first study to use a heart-failure specific primary
endpoint.8,14
If one observes new onset AF, asymptomatic ventricular tachycar-
dia, increasing frequency of ventricular extrasystoles, or decreasing
percentage of CRT pacing in a heart failure patient, we believe that it
is very plausible that a deterioration of the patient’s clinical status can
be prevented if the patient is seen within a few days. The lack of an
appropriate alert trigger, a failure to transmit the alert and accompa-
nying data or a significant lag before transmission, the inability to
judge the patient’s status from RM data, or the failure to contact the
patient without delay may be the reason for the failure to improve
clinical outcome. Too many of these details are unknown for too
many trials to dismiss IN-TIME as an outlier.
The observation that the clinical benefit of RM is restricted to
heart failure events suggests that it may be reasonable to establish a
monitoring unit especially for heart failure patients, possibly in co-
operation between device and heart failure clinics. IN-TIME had no
more than 140 patients under HM surveillance at any time, thus, even
medium size implanting centres may establish an efficient monitoring
team.
Conclusion
The difference between the IN-TIME result and other outcome stud-
ies may be caused by differences in content of transmitted data,
speed and completeness of transmission, and workflow to contact
the patient when needed. Both for clinical routine and for future
studies, we suggest to establish processes to assure a high transmis-
sion compliance in the long term, to use a wide array of medical data
to trigger alerts and to judge if a patient contact is needed, and to es-
tablish processes allowing to see the patient within less than 1 week
after a medically relevant event. Publications of work- and informa-
tion flow details from other studies—whether successful or not—
would be valuable to inform such planning.
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